Skip to main content

Anticoagulation and Continuous Renal Replacement Therapy (CRRT)

  • Chapter
  • First Online:
Pediatric Dialysis Case Studies
  • 816 Accesses

Abstract

Vascular access is one of the most important features in any extracorporeal therapy with data by Hackbarth suggesting optimal size and location effects on CRRT circuit patency. The choice of anticoagulation continues to be the style of practice with options of none (not advisable), heparin, citrate, and now prostacyclin. Comparison data of heparin to citrate suggest similar CRRT circuit life but with less risk of complications in the citrate arm.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hackbarth R, Bunchman TE, Chua AN, et al. The effect of vascular access location and size on circuit survival in pediatric continuous renal replacement therapy: a report from the PPCRRT registry. In J Artif Organs. 2007;30:1116–21.

    CAS  Google Scholar 

  2. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38(5):976–81.

    Article  CAS  PubMed  Google Scholar 

  3. Bunchman TE, Maxvold NJ, Barnett J, et al. Pediatric hemofiltration: Normocarb® dialysate solution with citrate anticoagulation. Pediatr Nephrol. 2002;17:150–4.

    Article  PubMed  Google Scholar 

  4. Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005;20:1416–21.

    Article  PubMed  Google Scholar 

  5. Zaoral T, Haldik M, Zapletalova J, et al. Circuit lifetime with citrate vs heparin in pediatric continuous venovenous hemodialysis. Pediatr Crit Care Med. 2016;17(9):e399–405.

    Article  PubMed  Google Scholar 

  6. Bunchman TE, Donckerwolcke RA. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol. 1994;8:96–102.

    Article  CAS  PubMed  Google Scholar 

  7. Chadha V, Garg U, Warady BA, et al. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol. 2002;17(10):819–24.

    Article  PubMed  Google Scholar 

  8. Goonaskeera CD, Wang J, Bunchman TE, Deep A. Factors affecting circuit life during continuous renal replacement therapy in children with liver failure. Ther Apher Dial. 2015;19(1):16–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy E. Bunchman .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bunchman, T.E. (2017). Anticoagulation and Continuous Renal Replacement Therapy (CRRT). In: Warady, B., Schaefer, F., Alexander, S. (eds) Pediatric Dialysis Case Studies. Springer, Cham. https://doi.org/10.1007/978-3-319-55147-0_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55147-0_38

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55145-6

  • Online ISBN: 978-3-319-55147-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics